article thumbnail

New Dodero Center at UH will Revolutionize Limb Salvage

DAIC

Led by Mehdi Shishehbor DO, MPH, PhD, interventional cardiologist and a pioneer in the field of limb preservation, the Dodero Center will revolutionize care for patients at risk of losing a leg due to peripheral artery disease and diabetes.

article thumbnail

Philips Enrolls First Patient in Clinical Trial for Integrated Single-Device to Treat PAD

DAIC

THOR IDE clinical trial, which will study an innovative combined laser atherectomy and intravascular lithotripsy catheter that integrates two critical PAD treatments into a single device. The innovative feature of the Philips catheter is that both the atherectomy and lithotripsy are laser-driven. clinical trial,” said Dr.

article thumbnail

Elixir Medical Receives FDA Breakthrough Device Designation for DynamX BTK System for Below-The-Knee Arterial Disease

DAIC

Peripheral arterial disease ( PAD ) affects more than 200 million people worldwide. The Bioadaptor platform was developed to transform treatment of coronary and peripheral artery disease,” said Motasim Sirhan, CEO at Elixir Medical , based in Milpitas, CA. Glob Heart. 2014;9(1):145-158 e121.

article thumbnail

Johnson and Johnson Completes Acquisition of Shockwave Medical

DAIC

Joaquin Duato , Chairman and Chief Executive Officer of Johnson & Johnson, said, “Through Innovative Medicine and MedTech, Johnson & Johnson is transforming the trajectory of cardiovascular disease, one of the leading causes of death globally.

article thumbnail

Groundbreaking Data in Interventional Cardiology to be Featured at Society for Cardiovascular Angiology and Interventions SCAI 2024 Scientific Sessions

DAIC

The Society for Cardiovascular Angiography & Interventions (SCAI) kicks off its SCAI Scientific Sessions 2024 this week, May 2-4 in Long Beach, CA, bringing together more than 1,800 clinicians, scientists, researchers, and innovators in the field of interventional cardiology and endovascular medicine.

article thumbnail

FDA Breakthrough Device Designation for Biotronik Freesolve Below-the-Knee Resorbable Magnesium Scaffold (RMS)

DAIC

CLTI is the most severe form of peripheral arterial disease (PAD), estimated to affect 11% of the 200 million people suffering from PAD globally. The Freesolve BTK RMS is designed for individuals suffering from chronic limb-threatening ischemia (CLTI). For more information: www.biotronik.com References: 1 Kwong M.,

article thumbnail

American Heart Month Puts Spotlight on Cardiovascular Disease and Stroke Statistics

DAIC

The article also includes links to DAIC channels (on peripheral artery disease, stroke, heart failure, peripheral artery disease, cardiovascular clinical studies, and more) focused on specific areas of news coverage. 1 in 3 adults with Type 2 diabetes may have undetected cardiovascular disease.